Matinas BioPharma Holdings, Inc.
MTNB · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.03 | 0.21 | 2.76 |
| FCF Yield | -640.12% | -32.99% | -18.49% | -7.29% |
| EV / EBITDA | 0.08 | -2.00 | -4.46 | -8.18 |
| Quality | ||||
| ROIC | -187.71% | -102.69% | -59.01% | -39.09% |
| Gross Margin | 0.00% | -1,221.99% | -423.15% | -2,244.50% |
| Cash Conversion Ratio | 0.66 | 0.67 | 0.91 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 221.44% | 172.05% | -28.38% |
| Free Cash Flow Growth | -2.51% | 22.71% | -29.48% | 10.88% |
| Safety | ||||
| Net Debt / EBITDA | 0.19 | 0.05 | 0.11 | 0.68 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -35.67 | -12.95 | -13.53 | -437.63 |